Travere Therapeutics, Inc.
NASDAQ:TVTX
13.48 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 145.238 | 212.018 | 227.49 | 198.321 | 175.338 | 164.246 | 154.937 | 133.591 | 99.892 | 28.203 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 56.382 | 7.592 | 6.784 | 6.126 | 5.234 | 5.527 | 3.605 | 4.554 | 2.185 | 0.571 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 88.856 | 204.426 | 220.706 | 192.195 | 170.104 | 158.719 | 151.332 | 129.037 | 97.707 | 27.632 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.612 | 0.964 | 0.97 | 0.969 | 0.97 | 0.966 | 0.977 | 0.966 | 0.978 | 0.98 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 237.729 | 235.78 | 210.328 | 131.773 | 140.963 | 123.757 | 78.168 | 70.853 | 50.426 | 47.795 | 7.084 | 0.663 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 265.542 | 220.206 | 149.883 | 135.799 | 128.951 | 103.654 | 103.958 | 98.015 | 79.541 | 59.645 | 16.888 | 30.257 | 0.013 | 0 | 0 | 0.013 |
| Selling & Marketing Expenses
| -37.671 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 227.871 | 220.206 | 149.883 | 135.799 | 128.951 | 103.654 | 103.958 | 98.015 | 79.541 | 59.645 | 16.888 | 30.257 | 0.013 | 0 | 0 | 0.013 |
| Other Expenses
| 1.594 | 0.974 | 0.231 | 1.42 | -0.314 | -0.474 | 1.107 | -0.264 | -0.296 | 570.979 | 0 | 28,964.721 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 465.6 | 455.986 | 360.211 | 267.572 | 269.914 | 227.411 | 182.126 | 168.868 | 129.967 | 107.44 | 23.972 | 30.257 | 0.013 | 0 | 0 | 0.013 |
| Operating Income
| -376.744 | -251.56 | -139.505 | -75.377 | -99.81 | -80.04 | -53.791 | -58.214 | -50.748 | -79.808 | -23.972 | -30.235 | -0.013 | 0 | 0 | -0.018 |
| Operating Income Ratio
| -2.594 | -1.187 | -0.613 | -0.38 | -0.569 | -0.487 | -0.347 | -0.436 | -0.508 | -2.83 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.634 | -26.609 | -40.177 | -113.413 | -46.638 | -28.864 | -26.381 | -16.992 | 146.075 | -21.434 | -9.729 | -0.003 | -0.002 | 0 | 0 | 0 |
| Income Before Tax
| -376.11 | -278.169 | -179.682 | -188.79 | -146.448 | -101.867 | -58.363 | -57.582 | 105.467 | -113.398 | -33.748 | -30.344 | -0.015 | 0 | 0 | -0.018 |
| Income Before Tax Ratio
| -2.59 | -1.312 | -0.79 | -0.952 | -0.835 | -0.62 | -0.377 | -0.431 | 1.056 | -4.021 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.223 | 0.313 | 0.409 | -19.359 | -0.021 | 0.811 | 1.368 | -9.679 | -11.77 | -2.46 | 0.076 | 0.003 | 0 | 0 | 0 | 0 |
| Net Income
| -111.399 | -278.482 | -180.091 | -169.431 | -146.427 | -102.678 | -59.731 | -47.903 | 117.237 | -110.938 | -33.824 | -30.344 | -0.015 | 0 | 0 | -0.018 |
| Net Income Ratio
| -0.767 | -1.313 | -0.792 | -0.854 | -0.835 | -0.625 | -0.386 | -0.359 | 1.174 | -3.934 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.5 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 | 3.49 | -4.43 | -2.38 | -8.29 | -0.14 | 0 | 0 | -0 |
| EPS Diluted
| -1.5 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.25 | 3.17 | -4.43 | -2.38 | -8.29 | -0.14 | 0 | 0 | -0 |
| EBITDA
| -331.812 | -244.31 | -137.281 | -68.954 | -69.661 | -63.667 | -29.687 | -6.968 | -33.156 | -52.972 | -14.027 | -30.11 | -0.013 | 0 | 0 | -0.018 |
| EBITDA Ratio
| -2.285 | -1.152 | -0.603 | -0.348 | -0.397 | -0.388 | -0.192 | -0.052 | -0.332 | -1.878 | 0 | 0 | 0 | 0 | 0 | 0 |